A study to determine the safe dose of iberdomide (CC-220) in combination with R-CHOP21 and CC-98282 in combination with R-CHOP21 in subjects with untreated aggressive B-cell lymphoma
Phase 1
Active, not recruiting
- Conditions
- ewly diagnosed aggressive B-cell lymphoma (a-BCL)MedDRA version: 20.1Level: LLTClassification code: 10080217Term: High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10012818Term: Diffuse large B-cell lymphoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10023699Term: Large B-cell lymphoma subtype primary mediastinal (Thymic) large B-cell lymphoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065863Term: Anaplastic large-cell lymphoma primary cutaneous type Class: 10029104MedDRA version: 23.0Level: PTClassification code: 10071977Term: Anaplastic lymphoma kinase gene mutation Class: 100000004850Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2023-506094-35-00
- Lead Sponsor
- Celgene Corp.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 174
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method